Extracorporeal hepatocyte-based therapy - Vital Therapies

Drug Profile

Extracorporeal hepatocyte-based therapy - Vital Therapies

Alternative Names: ELAD; Extracorporeal bio-artificial liver; VTL C3A

Latest Information Update: 11 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vital Therapies
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver failure
  • New Molecular Entity No

Highest Development Phases

  • Phase III Alcoholic hepatitis; Liver failure

Most Recent Events

  • 01 Mar 2018 Vital Therapeutics completes enrolment in the phase III VTL-308 trial for Alcoholic hepatitis and Liver failure in USA, Austria, Germany, Ireland, Spain and United Kingdom (EudraCT2015-004529-14; NCT02612428)
  • 23 May 2016 Vital Therapies initiates enrolment of patients in the VTI-308 trial for Alcoholic hepatitis and Liver failure (9196496; NCT02612428)
  • 08 Feb 2016 Phase-III clinical trials in Alcoholic hepatitis in Ireland (Extracorporeal) (EudraCT2015-004529-14)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top